Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery

This single-center, double-blind, randomized controlled trial aims to determine whether oliceridine for patient-controlled intravenous analgesia (PCIA) can significantly reduce the incidence of postoperative nausea, an opioid-related adverse reaction, compared to sufentanil PCIA in patients undergoing cerebellopontine angle (CPA) region surgery. A secondary objective is to compare the postoperative analgesic effects between the two drugs. The study plans to enroll 174 patients (with a calculated sample size of 164 plus 5% for attrition). The primary outcome is the incidence of nausea within 6-48 hours postoperatively. Secondary outcomes include pain scores at rest and during movement within 48 hours, and other exploratory outcomes such as vomiting incidence, time to first flatus/defecation, and gastrointestinal function scores.

NCT Number	NCT07479446
Lead Sponsor	Xuanwu Hospital, Beijing
Conditions	PONV, Cerebellopontine Angle Tumor, Microvascular Decompression Surgery, Postoperative Analgesia
Enrollment	174 participants
Start Date	2026-03-25
Primary Completion	2027-08-31 (estimated)
Study Completion	2027-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-22